Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Unmet needs in NETs

Michael Morse • 21 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Neuroendocrine Tumor Lanreotide depot Pembrolizumab
PLANET

Michael Morse, MD, Duke University Medical Center, Durham, NC, outlines areas of unmet needs for patients with neuroendocrine tumors (NETs) including rapid progression and low survival in patients with high-grade NETs. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Michael Morse

7:38
PLANET: pembrolizumab with lanreotide depot for advanced GEP-NETs
Michael Morse • 21 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals